Orlistat compositions
OwnerPierre Barbier, Paul Hadvary +1inventors
InventorsPierre Barbier, Paul Hadvary, Hans Lengsfeld
Life of this patent
Estimating the term…
Abstract
A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.
Claims37
A pharmaceutical composition which comprises orlistat and a pharmaceutically acceptable bile acid sequestrant selected from the group consisting of DEAE-cellulose, guanidinoethylcellulose, and DEAE-Sephadex.
A pharmaceutical composition which comprises orlistat and a pharmaceutically acceptable acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β-cyclodextrin, and γ-cyclodextrin.
A kit for use in the treatment of obesity, which comprises (a) a first component which is orlistat and (b) a second component which is a bile acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β-cyclodextrin, γ-cyclodextrin, guanidinoethylcellulose, and DEAE-Sephadex, present in oral unit dosage form.
A method of treating obesity in an obese patient to achieve a reduction in body weight, which comprises administering to a patient in need of such treatment (a) a therapeutically effective amount of orlistat and (b) a pharmaceutically acceptable bile acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β-cyclodextrin, γ-cyclodextrin, guanidinoethylcellulose, and DEAE-Sephadex in an amount effective to reduce gastrointestinal side effects associated with the lipase inhibitor.
Dependencies are inferred from the claim text.